Hormone tablets plus radiotherapy for certain endometrial cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial compares two ways to treat endometrial cancer after surgery: a new option of just radiotherapy plus a daily hormone tablet (progestin) versus the current standard of radiotherapy plus chemotherapy. It aims to see if the new option works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of endometrial cancer (such as endometrioid, serous, clear cell, or other listed types).
- Your tumor has been tested for specific molecular features — it must be a type called NSMP (not p53-mutated, not mismatch repair deficient, and not POLE-mutated).
- You have had surgery to remove your uterus and ovaries, with no visible cancer left behind.
- You have stage II or III cancer with certain risk features, and your tumor is estrogen receptor positive (ER+).
- You are 18 or older, able to care for yourself (WHO performance status 0 or 1), and have adequate kidney, liver, and blood cell function.
- You have not had pelvic radiation before and have no recent history of blood clots, heart disease, or other conditions that would rule out the treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called durvalumab to the usual treatment can improve outcomes for people with a specific genetic type of endometrial cancer that is at high risk of returning. It is designed for people who have already had surgery to remove the cancer.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a precise type of radiation (stereotactic radiotherapy) given after surgery for endometrial cancer. It aims to improve treatment while reducing side effects.
This early-phase study tests whether giving a short course of radiation together with chemotherapy can help treat endometrial cancer after surgery. It aims to find a treatment plan that is effective while keeping side effects manageable.
This trial compares chemotherapy alone versus chemotherapy plus radiation therapy for people with endometrial cancer that has a p53 mutation. The goal is to see which approach better prevents the cancer from coming back after surgery.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.